文献速递免疫规划传染病防控与疫情报告

基于病毒样纳米颗粒的中东呼吸综合征冠状病毒疫苗

Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.
PubMed 文献 · Vaccine · 2020-07-11

本文综述了针对中东呼吸综合征冠状病毒(MERS-CoV)的病毒样纳米颗粒(VLP)疫苗研究进展,指出VLP在动物模型中可有效控制MERS-CoV感染症状。由于SARS-CoV-2与MERS-CoV及SARS-CoV存在基因相似性,相关策略可加速SARS-CoV-2疫苗研发,并确保安全性、易接种和长期效果。

要点

  • VLP疫苗在MERS-CoV动物模型中显示可有效控制感染症状。
  • MERS-CoV可通过生物气溶胶从动物或人传播,患者死亡率高。
  • SARS-CoV-2与MERS-CoV基因相似,VLP策略可加速其疫苗研发。

核心结论

  • 基于病毒样纳米颗粒的疫苗在MERS-CoV动物模型中取得积极结果,可为SARS-CoV-2疫苗研发提供策略参考。

研究设计与样本

  • 本文为综述,聚焦于在MERS-CoV动物模型中取得成功的病毒样纳米颗粒研究。

主要发现

  • 病毒样纳米颗粒在MERS-CoV感染中可有效控制症状。
  • MERS-CoV可通过生物气溶胶从动物或人传播,患者死亡率高。
  • SARS-CoV-2与MERS-CoV及SARS-CoV存在基因相似性,可借鉴相关策略进行管理。

临床怎么用

  • 可借鉴MERS-CoV病毒样纳米颗粒疫苗策略,加速SARS-CoV-2疫苗研发并确保安全性、易接种和长期效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent advances in virus-like nanoparticles against Middle East respiratory syndrome-related coronavirus (MERS-CoV) can initiate vaccine production faster for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), while ensuring the safety, easy administration, and long-term effects. Patients with this viral pathogen suffer from excess mortality. MERS-CoV can spread through bioaerosol transmission from animal or human sources. The appearance of an outbreak in South Korea sparked off a strong urge to design strategies for developing an effective vaccine since the emergence of MERS-CoV in 2012. Well unfortunately, this is an important fact in virus risk management. The studies showed that virus-like nanoparticles (VLPs) could be effective in its goal of stopping the symptoms of MERS-CoV infection. Besides, due to the genetic similarities in the DNA sequencing of SARS-CoV-2 with MERS-CoV and the first identified severe acute respiratory syndrome (SARS-CoV) in China since 2002/2003, strategic approaches could be used to manage SARS-CoV 2. Gathering the vital piece of information obtained so far could lead to a breakthrough in the development of an effective vaccine against SARS-CoV-2, which is prioritized and focussed by the World Health Organization (WHO). This review focuses on the virus-like nanoparticle that got successful results in animal models of MERS-CoV.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hashemzadeh A, Avan A, Ferns GA, et al. Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus. Vaccine. 2020. PMID: 32684497. doi:10.1016/j.vaccine.2020.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。